NEW YORK, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report second quarter 2014 financial results after the NASDAQ Market closes on Monday, August 11, 2014. Intercept management will conduct a conference call and audio webcast on August 11, 2014 at 4:30 p.m. ET to discuss these results and provide an update on the company's business.
Mark Pruzanski, M.D., President and Chief Executive Officer, will also be presenting at the Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 10:20 a.m. ET in New York.
Dial-in and webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), alcoholic hepatitis, portal hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA has met the primary efficacy endpoint in five placebo-controlled clinical trials, including the recently completed POISE Phase 3 clinical trial in patients with PBC and two Phase 2 clinical trials in NASH and nonalcoholic fatty liver disease. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma (SDP). For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.
CONTACT: For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. Media inquiries: email@example.com Investor inquiries: firstname.lastname@example.org Source:Intercept Pharmaceuticals